✨Get 15% off, use code NYSTART2025
NSE

Neuron specific enolase

S-NSE

Neuron-specific enolase (S-NSE) is a biomarker used in medicine to assess nerve cell damage and monitor neuroendocrine tumors. S-NSE provides clinically relevant information about cellular damage, prognosis, and treatment response and is particularly significant in the diagnosis of neurological conditions and in prognostic evaluation after cardiac arrest.

Neuron-specific enolase (S-NSE) is an enzyme primarily found in nerve cells of the central and peripheral nervous systems. It is an isoform of enolase, an enzyme involved in glycolysis, the process by which cells convert glucose into energy. S-NSE is released into the bloodstream in the presence of nerve cell damage, such as hypoxic or ischemic injury, and is used to assess brain damage and neuroendocrine diseases.

S-NSE is also found in red blood cells and certain neuroectodermal tumors. This means that elevated levels can be observed without the presence of brain injury, for example, in cases of hemolysis or neuroectodermal tumors. However, the analysis is particularly sensitive to hemolysis.

The significance of S-NSE as a biomarker

S-NSE is used in various clinical settings, including:

  • Estimating the extent of cellular damage in brain injuries, including hypoxic/ischemic injuries.
  • Monitoring treatment response and progression of neuroendocrine tumors.
  • Serving as a prognostic marker after cardiac arrest.

One advantage of S-NSE is that it provides a quantitative measure unaffected by sedative medications, making it more reliable than many clinical examination findings or EEG.

S-NSE analysis after cardiac arrest

S-NSE is one of the most commonly used biomarkers for prognostic evaluation following cardiac arrest. Studies have shown that S-NSE levels can predict poor neurological outcomes. The largest study to date included 686 patients and revealed the following:

  • Threshold values: A value of ≥48 ng/ml at 48 hours or ≥38 ng/ml at 72 hours after cardiac arrest was associated with ≤2% false-positive results and 58% sensitivity for poor outcomes (based on the Roche analytical method).
  • Increasing trend: An increase in S-NSE between 24 and 48 hours after cardiac arrest reinforced the negative prognostic value.

For optimal clinical utility, a combination of high S-NSE values at 48 and 72 hours and a rising level between 24 and 48 hours is recommended as an indicator of poor outcome. Local threshold values should be adapted based on the specific analytical method used.

Applications of S-NSE

Diagnosis of neurological conditions

  • Traumatic brain injury and stroke: S-NSE can help assess the extent of injury and prognosis.
  • Hypoxic encephalopathy: Following oxygen deprivation, such as after cardiac arrest, S-NSE is used as an indicator of brain damage.
  • Neurodegenerative diseases: Elevated levels may occasionally be observed in Alzheimer’s and Parkinson’s disease.

Monitoring neuroendocrine tumors: S-NSE is used to monitor treatment response and progression of neuroendocrine tumors, particularly small-cell lung cancer. Elevated levels may indicate tumor burden, and reduced levels after treatment often suggest a positive response.

How is S-NSE analyzed?

S-NSE is analyzed through a blood test. The analysis is performed using methods such as:

  • ELISA (enzyme-linked immunosorbent assay)
  • Immunochemical techniques

To ensure accurate results, it is essential to avoid hemolysis during sample collection.

Interpretation of S-NSE test results

  • Normal levels: Indicate the absence of significant nerve damage or neuroendocrine tumors.
  • Elevated levels: May indicate brain injuries, neuroendocrine tumors, or other conditions affecting nerve cells.

Tests containing the marker S-NSE

Other health tests

Other health tests


NSE
Neuron-specific enolase

S-NSE

  • Blood analysis for S-NSE.
  • Neuron-specific enolase (NSE).
  • Blood test for the investigation of small cell lung cancer and nerve damage.
  • Recommended for suspected cancer or neurological diseases.

729 kr